Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Terminated Phase 2 Interventional

20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

NCT01568216
View directory record Official record
Conditions
Schizophrenia
Interventions
AMG 747, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Anaheim, California • Cerritos, California • Culver City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 17, 2026, 9:43 AM EDT
Recruiting Not applicable Interventional

Neuronal Effects of Exercise in Schizophrenia

NCT02455193
View directory record Official record
Conditions
Schizophrenia
Interventions
Exercise, Diet
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Treatment Study for Cognitive Deficits in Schizophrenia

NCT00505076
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-0777, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Not applicable Interventional

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

NCT00018642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine, haloperidol decanoate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Not applicable Interventional

Web-Based Weight Management for Individuals With Mental Illness

NCT01324973
View directory record Official record
Conditions
Mental Disorders, Schizophrenia, Affective Disorders, Psychotic, Overweight, Obesity
Interventions
eWellness
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 17, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 17, 2026, 9:43 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

NCT01900522
View directory record Official record
Conditions
Schizophrenia
Interventions
ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C, ITI-214 Dose D (Elderly), Placebo, ITI-214 Dose E, ITI-214 Dose F, ITI-214 Dose G, ITI-214 Dose H
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Glendale, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Web-based Support for People With Schizophrenia and Their Families

NCT00177983
View directory record Official record
Conditions
Relapse Rates Related to Website Usage
Interventions
(relapse rate)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Oct 17, 2026, 9:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Inter-Brain Synchrony in Schizophrenia

NCT07177261
View directory record Official record
Conditions
Schizophrenia Disorder
Interventions
Fast Friends, Small Talk
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Not applicable Interventional Results available

Brain Stimulation and Cognitive Training

NCT03338673
View directory record Official record
Conditions
Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
Interventions
tDCS, BrainHQ
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium

NCT02831231
View directory record Official record
Conditions
Schizophrenia
Interventions
xanomeline tartrate, Trospium chloride
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

NCT04092686
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856 75mg, SEP-363856 100mg, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
18
States / cities
Rogers, Arkansas • Anaheim, California • Bellflower, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

M1 Schizophrenia PET Study

NCT05105542
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Healthy
Interventions
11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor, PET Scan
Drug · Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Not applicable Interventional Results available

Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)

NCT00137280
View directory record Official record
Conditions
Schizophrenia, Chronic Illness, Weight Gain, Psychotic Disorder
Interventions
Collaborative Chronic Illness Care Model
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Long Beach, California • West Los Angeles, California • Shreveport, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Not applicable Interventional

Cognitive Remediation for Schizophrenia

NCT00261794
View directory record Official record
Conditions
Schizophrenia
Interventions
computer-assisted cognitive remediation (CACR), manualized computer control condition (RC).
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Phase 3 Interventional

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714713
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
69
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Not applicable Interventional Results available

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

NCT01152697
View directory record Official record
Conditions
Patient Noncompliance
Interventions
haloperidol decanoate, haloperidol, Customized Adherence Enhancement
Drug · Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 17, 2026, 9:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ascertaining Diagnosis Classification With Elicited Speech

NCT05601063
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders, Depressive Disorder, Anxiety Disorders, Personality Disorders, Attention Deficit Hyperactivity Disorder
Interventions
Winterlight Speech Assessment
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
14 Years to 50 Years
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Not applicable Interventional

Cognitive Remediation for Schizophrenia

NCT00295048
View directory record Official record
Conditions
Schizophrenia
Interventions
Computer Assisted Cognitive Remediation (CACR)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 17, 2026, 9:43 AM EDT
Terminated Phase 3 Interventional Results available

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

NCT01760993
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 17, 2026, 9:43 AM EDT
Recruiting Not applicable Interventional

Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways

NCT07469384
View directory record Official record
Conditions
SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Interventions
transcranial direct current stimulation, Sham stimulation
Device
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 17, 2026, 9:43 AM EDT
Terminated Not applicable Interventional Results available

Horyzons: Implementation and Integration in Clinical Practice

NCT06002958
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
Interventions
Horyzons USA
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 35 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dyad Oxytocin Study (DOS)

NCT02302209
View directory record Official record
Conditions
Schizophrenia, Autism Spectrum Disorder
Interventions
Oxytocin, Placebo Comparator
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 17, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

NCT00190749
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 17, 2026, 9:43 AM EDT